Andreas Wollenberg

1. Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*
   2020/10/01 by Andreas Wollenberg, A. Wollenberg, A. Blauvelt +39 · 36 citations
   Medicine · Immunology and Microbiology · #Dermatology and Skin Diseases #Allergic Rhinitis and Sensitization #Psoriasis: Treatment and Pathogenesis
2. Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phaseIIItrials
   2020/01/30 by Eric L. Simpson, E.L. Simpson, J.‐P. Lacour +43 · 29 citations
   Medicine · Immunology and Microbiology · #Dermatology and Skin Diseases #Psoriasis: Treatment and Pathogenesis #Allergic Rhinitis and Sensitization
3. Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials
   2022/09/09 by Eric L. Simpson, Joseph F. Merola, Jonathan I. Silverberg +13 · 27 citations
   Medicine · #Dermatology and Skin Diseases #Asthma and respiratory diseases #Allergic Rhinitis and Sensitization
4. Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS)
   2019/08/13 by A. Wollenberg, Andreas Wollenberg, L.A. Beck +24 · 26 citations
   Medicine · Immunology and Microbiology · #Dermatology and Skin Diseases #Psoriasis: Treatment and Pathogenesis #Asthma and respiratory diseases